HNL Lab Medicine Launches Strategic Preferred Partnership with Diasorin
HNL Lab Medicine is thrilled to announce a new Strategic Preferred Partnership with Diasorin, a global leader in in vitro diagnostics specializing in high-quality immunodiagnostic and molecular testing solutions. This collaboration is set to elevate laboratory capabilities, streamline testing processes, and drive forward improvements in patient care.
“This partnership with Diasorin marks an exciting new chapter for HNL Lab Medicine,” said Warren Erdmann, Chief Operating Officer of HNL Lab Medicine. “Working closely with Diasorin, a company known for their diagnostic expertise and cutting-edge technology, enables us to boost testing accuracy, efficiency, and responsiveness.” Erdmann emphasized that the partnership would enhance resource accessibility, especially with Diasorin’s nearby presence facilitating fast turnaround and reliable support for lab operations.
The synergy between HNL Lab Medicine’s focus on operational excellence and Diasorin’s diagnostic advancements aims to redefine laboratory efficiency and patient care standards. Together, both organizations are well-positioned to tackle the increasing demands of the healthcare industry, setting a new benchmark in service quality and innovation.
Diasorin, which shares HNL Lab Medicine’s commitment to healthcare advancements, is equally optimistic about this partnership. Dustin Stewart, SVP, Commercial Operations N.A., at Diasorin, expressed his enthusiasm for the collaboration, stating, “We are thrilled to partner with HNL Lab Medicine to deliver advanced diagnostic solutions that enhance patient care and support healthcare providers with reliable, innovative technologies.” Diasorin’s dedication to high-precision diagnostics aligns seamlessly with HNL Lab Medicine’s mission, allowing both to bring their strengths together to benefit patients and providers alike. 
The Preferred Partnership is anchored in three core pillars: delivering high-quality diagnostic results, providing exceptional service to patients and healthcare providers, and ensuring a sustainable model that supports continuous reinvestment in technology, facilities, and staff. With Diasorin’s expertise and HNL Lab Medicine’s operational strengths, the partnership aims to drive innovation, enhance testing capabilities, and contribute to superior healthcare solutions in a dynamic landscape.
This alliance is part of HNL Lab Medicine’s Strategic Preferred Partnerships Program, an initiative designed to build long-term, impactful relationships with leading industry innovators. Through partnerships like these, HNL Lab Medicine is dedicated to shaping the future of laboratory medicine, enhancing patient outcomes, and fostering sustainable growth in the healthcare field.